Bill Text: TX HB2462 | 2023-2024 | 88th Legislature | Introduced


Bill Title: Relating to disclosure of certain complaint and investigation information by the Texas State Board of Pharmacy to the United States Food and Drug Administration.

Spectrum: Partisan Bill (Republican 1-0)

Status: (Introduced - Dead) 2023-04-24 - Left pending in committee [HB2462 Detail]

Download: Texas-2023-HB2462-Introduced.html
  88R2171 KBB-F
 
  By: Klick H.B. No. 2462
 
 
 
A BILL TO BE ENTITLED
 
AN ACT
  relating to disclosure of certain complaint and investigation
  information by the Texas State Board of Pharmacy to the United
  States Food and Drug Administration.
         BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
         SECTION 1.  Section 555.010, Occupations Code, is amended to
  read as follows:
         Sec. 555.010.  CONFIDENTIALITY; AUTHORIZED DISCLOSURE.  (a)  
  Subject to Subsection (b), the [The] identity of a person who
  reports to or assists the board under Section 555.002(c) and a
  document that could disclose the identity of that person are
  confidential and are not considered public information for the
  purposes of Chapter 552, Government Code.
         (b)  The identity of a person described by Subsection (a) and
  a document that could disclose the identity of that person may be
  disclosed to the United States Food and Drug Administration under a
  memorandum of understanding described by Section 503A, Federal
  Food, Drug, and Cosmetic Act (21 U.S.C. Section 353a(b)(3)(B)),
  entered into as provided by that section.
         SECTION 2.  Section 565.055(c), Occupations Code, is amended
  to read as follows:
         (c)  Notwithstanding Subsection (b), information or material
  compiled by the board in connection with an investigation may be
  disclosed:
               (1)  during any proceeding conducted by the State
  Office of Administrative Hearings, to the board, or a panel of the
  board, or in a subsequent trial or appeal of a board action or
  order;
               (2)  to a person providing a service to the board,
  including an expert witness, investigator, or employee of an entity
  that contracts with the board, related to a disciplinary proceeding
  against an applicant or license holder, or a subsequent trial or
  appeal, if the information is necessary for preparation for, or a
  presentation in, the proceeding;
               (3)  to an entity in another jurisdiction that:
                     (A)  licenses or disciplines pharmacists or
  pharmacies; or
                     (B)  registers or disciplines pharmacy
  technicians or pharmacy technician trainees;
               (4)  to a pharmaceutical or pharmacy peer review
  committee as described under Chapter 564;
               (5)  to a law enforcement agency;
               (6)  to a person engaged in bona fide research, if all
  information identifying a specific individual has been deleted;
  [or]
               (7)  to an entity that administers a board-approved
  pharmacy technician certification examination; or
               (8)  to the United States Food and Drug Administration
  under a memorandum of understanding described by Section 503A,
  Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section
  353a(b)(3)(B)), entered into as provided by that section.
         SECTION 3.  This Act takes effect September 1, 2023.
feedback